Hematologic Oncology

Timothy Hughes, MD, MBBS, FRACP, FRCPA, on safety data for asciminib in Philadelphia chromosome–positive chronic-phase chronic myeloid leukemia.

Dr. Hannah Choe discusses a clinical scenario of a patient with GVHD who has progressed after multiple lines of treatment. She explores how the availability of CSF-1R inhibitors could fit into the evolving treatment landscape for managing this difficult-to-treat patient population. Dr. Choe provides her perspectives on the potential role and clinical implications of targeting this pathway as an emerging therapeutic approach for GVHD.

Dr. Hannah Choe reviews data from the AGAVE-201 trial investigating the CSF-1R inhibitor axatilimab, including efficacy, safety, and clinical implications of these data for patients with recurrent or refractory chronic GVHD.

Odronextamab elicited deep, durable responses in heavily pretreated patients with relapsed/refractory follicular lymphoma.

Brentuximab vedotin plus lenalidomide/rituximab (R2) provided a superior overall survival benefit vs R2 alone in relapsed/refractory DLBCL.

The BLA for tabelecleucel has been granted priority review for the treatment of patients with Epstein-Barr virus–positive post-transplant lymphoproliferative disease.

Grzegorz S. Nowakowski, MD, discusses the significance of the FDA approval of epcoritamab in relapsed/refractory follicular lymphoma.

Francisco Hernandez-Ilizaliturri, MD, discusses selection and sequencing considerations for bispecific antibodies and CAR T-cell therapies in DLBCL.

The FDA has placed a partial clinical hold on a trial evaluating seclidemstat plus azacitidine in myelodysplastic syndromes or chronic myelomonocytic leukemia.

Francisco Hernandez-Ilizaliturri, MD, details factors that influence CAR T-cell therapy selection in relapsed/refractory follicular lymphoma.

The investigational menin-MLL inhibitor DSP-5336 has received FDA fast track designation in KMT2A-rearranged/NPM1-mutant acute myeloid leukemia.

Moleculin Biotech completed an end-of-phase 2 meeting with the FDA regarding the investigation of annamycin plus cytarabine in acute myeloid leukemia.

Pamela J Sung, MD, PhD, details differentiation therapy in acute myeloid leukemia, focusing on newer targets and preclinical evidence for a novel FLT3 combination.

Preliminary results for treatment with zanubrutinib + venetoclax in patients with high-risk TN CLL/SLL with del(17p) and/or TP53 mutation showed Promising efficacy in a high-risk population with deep and durable responses according to data from arm D of the phase 3 SEQUOIA trial (NCT03336333).

SLS009 has been granted orphan drug designation by the EMA for the treatment of patients with acute myeloid leukemia.

Tycel Phillips, MD, highlights key takeaways in NHL, MDS, and myelofibrosis from an OncLive State of the Science Summit on hematology.

Up to 12 months of treatment with SGX301 produced lesion responses in patients with early-stage cutaneous T-cell lymphoma.

GLPG5101 produced high CRs in patients with relapsed/refractory non-Hodgkin lymphoma, indicating the feasibility of decentralized CAR T manufacturing.

The BLA seeking approval for remestemcel-L for children with steroid-refractory acute graft-vs-host-disease has been resubmitted to the FDA.

BGB-16673-101 (NCT05006716) is a phase 1 study of a bruton tyrosine kinase degrader (BGB-16673) in patients with relapsed or refractory CLL/SLL.

DREAMM-8 (NCT04484623) is an ongoing, randomized, open-label, phase 3 study evaluating BPd vs PVd in patients with RRMM previously treated with ≥1 line of therapy including lenalidomide.

Dr. Choe discusses the potential role of the CSF-1R signaling pathway in the pathogenesis of numerous diseases, including GVHD. A video segment explores how dysregulation of this pathway can contribute to the development and progression of GVHD, providing the rationale for targeting CSF-1R as a potential therapeutic strategy.

In this video, Dr. Hannah Choe provides an overview of the background of graft-versus-host disease (GVHD), discusses currently approved treatments and their limitations, and the significant unmet treatment needs in GVHD.

Selinexor has received approval as monotherapy for the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma in China.

KT-333 was well tolerated in relapsed/refractory hematologic and solid tumor cancers, including cutaneous T-cell lymphoma and peripheral T-cell lymphoma.